DK3536324T3 - 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 - Google Patents
4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 Download PDFInfo
- Publication number
- DK3536324T3 DK3536324T3 DK19152036.0T DK19152036T DK3536324T3 DK 3536324 T3 DK3536324 T3 DK 3536324T3 DK 19152036 T DK19152036 T DK 19152036T DK 3536324 T3 DK3536324 T3 DK 3536324T3
- Authority
- DK
- Denmark
- Prior art keywords
- gpr139
- benzotriazines
- modulators
- dihydro
- oxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462082539P | 2014-11-20 | 2014-11-20 | |
US201562184729P | 2015-06-25 | 2015-06-25 | |
EP15816275.0A EP3221298B1 (en) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine derivatives as modulators of gpr139 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3536324T3 true DK3536324T3 (da) | 2021-10-25 |
Family
ID=55022667
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19152036.0T DK3536324T3 (da) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 |
DK15816275.0T DK3221298T3 (da) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15816275.0T DK3221298T3 (da) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriazinderivater som modulatorer af gpr139 |
Country Status (40)
Country | Link |
---|---|
US (5) | US9556130B2 (da) |
EP (2) | EP3536324B1 (da) |
JP (2) | JP6637501B2 (da) |
KR (1) | KR102582021B1 (da) |
CN (2) | CN112062730B (da) |
AU (1) | AU2015349866B2 (da) |
BR (1) | BR112017010311A2 (da) |
CA (1) | CA2968242C (da) |
CL (1) | CL2017001292A1 (da) |
CO (1) | CO2017005959A2 (da) |
CR (1) | CR20170275A (da) |
CY (2) | CY1122613T1 (da) |
DK (2) | DK3536324T3 (da) |
DO (1) | DOP2017000120A (da) |
EA (1) | EA033728B1 (da) |
EC (1) | ECSP17038999A (da) |
ES (2) | ES2897545T3 (da) |
GE (1) | GEP20196961B (da) |
HR (2) | HRP20212009T1 (da) |
HU (2) | HUE044145T2 (da) |
IL (1) | IL252311B (da) |
JO (1) | JO3719B1 (da) |
LT (2) | LT3536324T (da) |
MA (1) | MA40993B1 (da) |
MD (1) | MD3221298T2 (da) |
MX (1) | MX2017006448A (da) |
MY (1) | MY187423A (da) |
NZ (1) | NZ732208A (da) |
PE (1) | PE20170899A1 (da) |
PH (1) | PH12017500920A1 (da) |
PL (2) | PL3536324T3 (da) |
PT (2) | PT3536324T (da) |
RS (2) | RS59078B1 (da) |
SG (1) | SG11201704002UA (da) |
SI (2) | SI3221298T1 (da) |
TN (1) | TN2017000196A1 (da) |
TW (1) | TWI684590B (da) |
UA (1) | UA120375C2 (da) |
UY (1) | UY36406A (da) |
WO (1) | WO2016081736A1 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3719B1 (ar) | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
CA3121108A1 (en) | 2018-10-16 | 2020-04-23 | The Scripps Research Institute | Methods related to opioid therapeutics |
WO2020097609A1 (en) | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
KR20220063228A (ko) | 2019-09-16 | 2022-05-17 | 다케다 야쿠힌 고교 가부시키가이샤 | 아졸-융합된 피리다진-3(2h)-온 유도체 |
WO2021127459A1 (en) * | 2019-12-20 | 2021-06-24 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
US20230227416A1 (en) * | 2020-05-08 | 2023-07-20 | Takeda Pharmaceutical Company Limited | Substituted benzotriazinone metabolites of a gpr139 agonist |
JP2023541485A (ja) | 2020-09-21 | 2023-10-02 | 武田薬品工業株式会社 | 統合失調症のための処置 |
US11760788B2 (en) | 2021-03-02 | 2023-09-19 | Pathways Neuro Pharma, Inc. | Neuroreceptor compositions and methods of use |
WO2023165262A1 (zh) * | 2022-03-01 | 2023-09-07 | 上海科技大学 | 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用 |
WO2023165263A1 (zh) * | 2022-03-01 | 2023-09-07 | 上海科技大学 | 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用 |
CN117986183A (zh) * | 2022-10-28 | 2024-05-07 | 浙江友宁生物医药科技有限公司 | 一种gpr139受体激动剂、其制备方法及其应用 |
WO2024102802A1 (en) * | 2022-11-11 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Zelatriazin for the treatment of depression |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3794726A (en) * | 1972-08-21 | 1974-02-26 | Uniroyal Inc | Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one |
US4959368A (en) | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
ATE108791T1 (de) * | 1987-11-04 | 1994-08-15 | Beecham Group Plc | Neue 4-oxobenzotriazine und 4-oxochinazoline. |
WO2004108673A2 (en) | 2003-06-09 | 2004-12-16 | Boehringer Ingelheim International Gmbh | Inhibitors of papilloma virus |
MXPA06001081A (es) | 2003-07-31 | 2006-04-24 | Irm Llc | Compuestos biciclicos y composiciones como inhibidores de pdf. |
FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
AR058705A1 (es) | 2005-12-23 | 2008-02-20 | Astrazeneca Ab | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
CA2680775A1 (en) * | 2007-03-23 | 2008-10-02 | F. Hoffmann-La Roche Ag | Aza-pyridopyrimidinone derivatives |
JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
WO2014152917A2 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | Physiological ligands for gpr139 |
JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
-
2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/en active Active
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active IP Right Grant
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 CA CA2968242A patent/CA2968242C/en active Active
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 MX MX2017006448A patent/MX2017006448A/es unknown
- 2015-11-19 BR BR112017010311A patent/BR112017010311A2/pt active Search and Examination
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/en active Active
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/en active Application Filing
-
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
-
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920A1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
-
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
-
2019
- 2019-06-03 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
-
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
-
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3536324T3 (da) | 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 | |
DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
BR112016030368A2 (pt) | composição oftálmica | |
DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
DK3636649T3 (da) | Diarylmakrocykler som modulatorer af proteinkinaser | |
DK3357919T3 (da) | Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser | |
DK3131902T3 (da) | Forbindelser som ROR-gamma-modulatorer | |
DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
DK3094631T3 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
DK3331863T3 (da) | Hidtil ukendte forbindelser som ror-gamma-modulatorer | |
DK3204378T6 (da) | N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen | |
DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
DK3220891T3 (da) | Sublingual formulering af riluzol | |
DK3212643T3 (da) | Trifluormethylalkoholer som modulatorer af ror-gamma-t | |
DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
DK3122349T3 (da) | Sammensætninger til behandling af autodigestion | |
DK3418273T3 (da) | Derivater af flavagliner | |
DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
DK3611890T3 (da) | Signalering af modulationskonfiguration | |
DK3173071T3 (da) | Formularing af maropitant |